Lauralee Donaldson v. Eurofins MTS Consumer Product Testing US, LLC

CourtDistrict Court, D. Massachusetts
DecidedFebruary 27, 2026
Docket1:26-cv-11305
StatusUnknown

This text of Lauralee Donaldson v. Eurofins MTS Consumer Product Testing US, LLC (Lauralee Donaldson v. Eurofins MTS Consumer Product Testing US, LLC) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lauralee Donaldson v. Eurofins MTS Consumer Product Testing US, LLC, (D. Mass. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT LAURALEE DONALDSON, ) 3:24-CV-01736 (SVN) Plaintiff, ) ) v. ) ) EUROFINS MTS CONSUMER ) PRODUCT TESTING US, LLC, ) Defendant. ) February 27, 2026

ORDER GRANTING IN PART DEFENDANT’S MOTION TO DISMISS AND TRANSFERRING ACTION Sarala V. Nagala, United States District Judge. In this employment action, Plaintiff Lauralee Donaldson alleges that Defendant Eurofins MTS Consumer Product Testing US, LLC (“Eurofins”) wrongfully terminated her employment due to erroneous drug screening results. Sec. Am. Compl. (“SAC”), ECF No. 45. The second amended complaint consists of three claims: common law wrongful termination, common law negligence, and a violation of Conn. Gen. Stat. §§ 31-51t–u, which prohibit subjecting an employee to an adverse employment action based on a single drug testing result alone, under certain circumstances. Eurofins seeks to dismiss Plaintiff’s SAC, claiming that this Court does not have personal jurisdiction over it; and in the alternative, Eurofins argues that this case should be transferred to the District of Massachusetts. Eurofins also argues that, in any event, the SAC fails to state a claim for relief. See Am. Mot. to Dismiss, ECF No. 50. Plaintiff opposes the motion. Opp. Mot. to Dismiss, ECF No. 56. For the reasons described below, the Court holds that it lacks personal jurisdiction over Eurofins and thus grants Eurofins’ motion to dismiss in part. Further, the Court exercises its discretion to transfer this action to the District of Massachusetts. I. FACTUAL BACKGROUND A. Factual Allegations

The following allegations are accepted as true for the purposes of the motion to dismiss. See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). In the spring of 2024, Plaintiff received a call from Eurofins’ director of business development, Anthony Hernandez, inquiring about whether she was interested in working with the company. ECF No. 45 ¶ 10. Plaintiff expressed interest in a job opportunity, and Mr. Hernandez advised her to reach out to his supervisor, Mr. Seemanta Mitra, which Plaintiff did. Id. ¶¶ 13–14. Plaintiff met with Mr. Hernandez and Mr. Mitra on two occasions, and received a verbal offer of employment at each meeting. Id. ¶¶ 16–18, 22–23. On June 26, 2024, Plaintiff received an official offer of employment from Eurofins via email, along with a request that she complete a drug screening and background check. Id. ¶¶ 25–

26. Plaintiff completed the background check on July 2, 2024. Id. ¶ 26. On July 5, 2024, Plaintiff provided her sample1 for the drug screening to Accurate Background, LLC (“Accurate”).2 Id. ¶ 27. Plaintiff observed that the drug testing location, operated by a third party, “also served as an unsanitary methadone clinic,” and alleges that a technician at the location informed her that her sample may have been “insufficient for testing.” Id. ¶¶ 28–29.

1 Plaintiff’s complaint suggests she provided a “blood sample,” see id. ¶ 49, but in her response to Eurofins’ motion, she indicates she provided a urine sample, see ECF No. 56 at 12. 2 Eurofins filed a third-party complaint against Accurate Background, LLC, asserting claims for negligence, negligent misrepresentation, indemnification, and contribution. See Third Party Compl., ECF No. 57 ¶¶ 20–33. It has since sought to dismiss the third-party complaint, see Mot. to Dismiss, ECF No. 83, which the Court has granted, ECF No. 86. Plaintiff started working at Eurofins on July 8, 2024. Id. ¶ 32. Eight days later, Plaintiff was informed by Eurofins that her drug screening indicated positive results for cocaine. Id. ¶¶ 33–35. In response, Plaintiff explained to Eurofins that she takes a prescription medication that may have impacted her results. Id. ¶¶ 34–35. Plaintiff later shared a photograph of her prescription with Eurofins. Id. ¶ 47. Plaintiff also alleges that she has adverse reactions to opiate-

based substances and always refuses them when offered by medical providers, as reflected in her medical records. Id. ¶¶ 36–37. Plaintiff attempted to ascertain more information about the drug screening results. She contacted her prescribing doctor, who reminded her that her recent bloodwork did not indicate any drug use and advised she retest at a new facility. Id. ¶ 38. She also attempted to contact Accurate regarding her results and share with them a copy of her prescription, but its customer service representatives could not locate any record of her drug screening. Id. ¶ 39. A representative for Eurofins informed Plaintiff that it would conduct an investigation with Accurate, but Plaintiff was not provided with the results of that investigation. Id. ¶ 40. After

multiple attempts to contact Eurofins regarding her problems communicating with Accurate, Eurofins’ representative provided Plaintiff with three additional phone numbers for Accurate. Id. ¶¶ 41–43. Plaintiff attempted to inquire about her results at these phone numbers, but encountered the same problem: no one could locate the record of her drug screening. Id. ¶ 43. A representative for Eurofins also told Plaintiff she would attempt to contact Accurate, which did not yield any results. Id. ¶ 46. On July 26, 2024, a representative for Eurofins ordered a new drug test for Plaintiff and apologized for the issues Plaintiff had encountered surrounding her drug screening. Id. ¶ 48. However, on a call later that same day, Eurofins informed Plaintiff that she actually would not be permitted to provide a new sample, despite her willingness to do so. Id. ¶¶ 49–50. Instead, Accurate could only retest her original specimen. See id. ¶ 49. On the call, Eurofins indicated that Plaintiff could take an entirely new test if she was willing to cover the cost herself, and Plaintiff responded that she was willing to do so. Id. ¶ 50. Plaintiff then called Accurate to request a retest of the original specimen, but Accurate informed her that the specimen was no

longer available to be tested. Id. ¶ 52. Two hours later, Eurofins terminated Plaintiff’s employment. Id. ¶ 53. Plaintiff sent an email to representatives of Eurofins contesting the decision to terminate her employment, but received no response; on August 9, 2024, Plaintiff received a letter from Eurofins confirming her termination. Id. ¶¶ 55–56. Plaintiff alleges, upon information and belief, that another Eurofins employee encountered similar errors in his drug test, but was permitted to undergo a second screening. Id. ¶ 57. Plaintiff alleges that she was very cooperative in attempting to resolve a potential mistake in her drug screening, but instead of working with her to retest the sample, Eurofins opted to

wrongfully terminate her employment. Id. ¶¶ 58–59. She further alleges that Eurofins acted negligently by subjecting her to a mishandled drug screening, failing to afford her the opportunity to re-test, and terminating her employment. Id. ¶ 71. The complaint contains three counts: (1) common law wrongful discharge in violation of public policy; (2) negligence; and (3) a claim for damages pursuant to Conn. Gen. Stat. § 31-51z, which permits an “aggrieved person” to file a civil action relating to violations of Conn. Gen. Stat. § 31-51t–u, such as when an employer terminates an employee based on a positive urinalysis test that is not confirmed by a second urinalysis test conducted in a manner specified by the statute. Id. ¶¶ 60–91. B.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Milliken v. Meyer
311 U.S. 457 (Supreme Court, 1941)
International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Goldlawr, Inc. v. Heiman
369 U.S. 463 (Supreme Court, 1962)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Chloé v. Queen Bee of Beverly Hills, LLC
616 F.3d 158 (Second Circuit, 2010)
Jazini v. Nissan Motor Company, Ltd.
148 F.3d 181 (Second Circuit, 1998)
Pino Distefano v. Carozzi North America, Inc.
286 F.3d 81 (Second Circuit, 2001)
MacDermid, Inc. v. Deiter
702 F.3d 725 (Second Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Lauralee Donaldson v. Eurofins MTS Consumer Product Testing US, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lauralee-donaldson-v-eurofins-mts-consumer-product-testing-us-llc-mad-2026.